Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors
- 9 November 2020
- journal article
- research article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 25 (8) , 2091-2100
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81773080)
This publication has 39 references indexed in Scilit:
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaJournal for ImmunoTherapy of Cancer, 2018
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patientsOncoImmunology, 2016
- Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinibCancer, 2015
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal TumorsCancer Research, 2013
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal TumorsJournal of the National Comprehensive Cancer Network, 2010
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2004
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002